Immunotherapy for tuberculosis: future prospects

References

• World Health OrganizationGlobal Tuberculosis ReportGenevaWorld Health Organization2014
   Google Scholar
• SinanovicERammaLVassallAImpact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South AfricaInt J Tuberc Lung Dis201519217217825574915
   PubMed Web of Science ®Google Scholar
• PietersenEIgnatiusEStreicherEMLong-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort studyLancet201438399241230123924439237
   PubMed Web of Science ®Google Scholar
• Working Group on New TB DrugsDrug Pipeline Available from: http://www.newtbdrugs.org/pipeline.phpAccessed January 25, 2016
   Google Scholar
• CorperHJCohnMLThe viability and virulence of old cultures of tubercle bacilli; studies on 30-year-old broth cultures maintained at 37 degrees CTubercle1951321123223714893467
   PubMedGoogle Scholar
• WayneLGDormancy of Mycobacterium tuberculosis and latency of diseaseEur J Clin Microbiol Infect Dis199413119089147698116
   PubMed Web of Science ®Google Scholar
• WayneLGHayesLGAn in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistenceInfect Immun1996646206220698675308
   PubMed Web of Science ®Google Scholar
• WayneLGIn Vitro model of hypoxically induced nonreplicating persistence of Mycobacterium tuberculosisMethods Mol Med20015424726921341080
   PubMedGoogle Scholar
• BarryCE3rdBoshoffHIDartoisVThe spectrum of latent tuberculosis: rethinking the biology and intervention strategiesNat Rev Microbiol200971284585519855401
   PubMed Web of Science ®Google Scholar
• LinPLFlynnJLUnderstanding latent tuberculosis: a moving targetJ Immunol20101851152220562268
   PubMed Web of Science ®Google Scholar
• BrighentiSAnderssonJInduction and regulation of CD8+ cytolytic T cells in human tuberculosis and HIV infectionBiochem Biophys Res Commun20103961505720494110
   PubMed Web of Science ®Google Scholar
• SederRADarrahPARoedererMT-cell quality in memory and protection: implications for vaccine designNat Rev Immunol20088424725818323851
   PubMed Web of Science ®Google Scholar
• HanQBagheriNBradshawEMHaflerDALauffenburgerDALoveJCPolyfunctional responses by human T cells result from sequential release of cytokinesProc Natl Acad Sci U S A201210951607161222160692
   PubMed Web of Science ®Google Scholar
• YaoSHuangDChenCYDifferentiation, distribution and gammadelta T cell-driven regulation of IL-22-producing T cells in tuberculosisPLoS Pathog201062e100078920195465
   PubMed Web of Science ®Google Scholar
• LiBRossmanMDImirTDisease-specific changes in gammadelta T cell repertoire and function in patients with pulmonary tuberculosisJ Immunol19961579422242298892660
   PubMed Web of Science ®Google Scholar
• Montamat-SicotteDJMillingtonKAWillcoxCRA mycolic acid-specific CD1-restricted T cell population contributes to acute and memory immune responses in human tuberculosis infectionJ Clin Invest201112162493250321576820
   PubMed Web of Science ®Google Scholar
• ChuaWJTruscottSMEickhoffCSBlazevicAHoftDFHansenTHPolyclonal mucosa-associated invariant T cells have unique innate functions in bacterial infectionInfect Immun20128093256326722778103
   PubMed Web of Science ®Google Scholar
• GoldMCCerriSSmyk-PearsonSHuman mucosal associated invariant T cells detect bacterially infected cellsPLoS Biol201086e100040720613858
   PubMed Web of Science ®Google Scholar
• ParkHDGuinnKMHarrellMIRv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosisMol Microbiol200348383384312694625
   PubMed Web of Science ®Google Scholar
• TufarielloJMMiKXuJDeletion of the Mycobacterium tuberculosis resuscitation-promoting factor Rv1009 gene results in delayed reactivation from chronic tuberculosisInfect Immun20067452985299516622237
   PubMed Web of Science ®Google Scholar
• KanaBDGordhanBGDowningKJThe resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitroMol Microbiol200867367268418186793
   PubMed Web of Science ®Google Scholar
• Russell-GoldmanEXuJWangXChanJTufarielloJMA Mycobacterium tuberculosis Rpf double-knockout strain exhibits profound defects in reactivation from chronic tuberculosis and innate immunity phenotypesInfect Immun20087694269428118591237
   PubMed Web of Science ®Google Scholar
• NossEHHardingCVBoomWHMycobacterium tuberculosis inhibits MHC class II antigen processing in murine bone marrow macrophagesCell Immunol20002011637410805975
   PubMed Web of Science ®Google Scholar
• PaiRKConveryMHamiltonTABoomWHHardingCVInhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasionJ Immunol2003171117518412816996
   PubMed Web of Science ®Google Scholar
• BoomWHCanadayDHFultonSAGehringAJRojasRETorresMHuman immunity to M. tuberculosis: T cell subsets and antigen processingTuberculosis (Edinb)2003831–39810612758197
   PubMed Web of Science ®Google Scholar
• Sturgill-KoszyckiSSchlesingerPHChakrabortyPLack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPaseScience199426351476786818303277
   PubMed Web of Science ®Google Scholar
• PetheKSwensonDLAlonsoSAndersonJWangCRussellDGIsolation of Mycobacterium tuberculosis mutants defective in the arrest of phagosome maturationProc Natl Acad Sci USA200410137136421364715340136
   PubMed Web of Science ®Google Scholar
• RohdeKYatesRMPurdyGERussellDGMycobacterium tuberculosis and the environment within the phagosomeImmunol Rev2007219375417850480
   PubMed Web of Science ®Google Scholar
• TingLMKimACCattamanchiAErnstJDMycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1J Immunol199916373898390610490990
   PubMed Web of Science ®Google Scholar
• KincaidEZErnstJDMycobacterium tuberculosis exerts gene-selective inhibition of transcriptional responses to IFN-gamma without inhibiting STAT1 functionJ Immunol200317142042204912902509
   PubMed Web of Science ®Google Scholar
• NagabhushanamVSolacheATingLMEscaronCJZhangJYErnstJDInnate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gammaJ Immunol200317194750475714568951
   PubMed Web of Science ®Google Scholar
• FortuneSMSolacheAJaegerAMycobacterium tuberculosis inhibits macrophage responses to IFN-gamma through myeloid differentiation factor 88-dependent and -independent mechanismsJ Immunol2004172106272628015128816
   PubMed Web of Science ®Google Scholar
• BanaieeNKincaidEZBuchwaldUJacobsWRJrErnstJDPotent inhibition of macrophage responses to IFN-gamma by live virulent Mycobacterium tuberculosis is independent of mature mycobacterial lipoproteins but dependent on TLR2J Immunol200617653019302716493060
   PubMed Web of Science ®Google Scholar
• BensonSAErnstJDTLR2-dependent inhibition of macrophage responses to IFN-gamma is mediated by distinct, gene-specific mechanismsPLoS One200947e632919629181
   PubMed Web of Science ®Google Scholar
• WangPWangLZhangWImmunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in miceHum Vaccin Immunother201410115015823982126
   PubMed Web of Science ®Google Scholar
• YangXYChenQFLiYPWuSMMycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysisPLoS One201169e2382621909406
   PubMed Web of Science ®Google Scholar
• YangSLiFJiaSEarly secreted antigen ESAT-6 of Mycobacterium Tuberculosis promotes apoptosis of macrophages via targeting the microRNA155-SOCS1 interactionCell Physiol Biochem20153541276128825721573
   PubMedGoogle Scholar
• Van RhijnIMoodyDBCD1 and mycobacterial lipids activate human T cellsImmunol Rev2015264113815325703557
   PubMed Web of Science ®Google Scholar
• DeyBDeyRJCheungLSA bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosisNat Med201521440140625730264
   PubMed Web of Science ®Google Scholar
• JohnsonJLKamyaRMOkweraARandomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research CollaborationJ Infect Dis200018141304131210753731
   PubMed Web of Science ®Google Scholar
• JohnsonJLNunnAJFouriePBEffect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosisInt J Tuberc Lung Dis20048111348135415581204
   PubMed Web of Science ®Google Scholar
• ButovDAEfremenkoYVPrihodaNDRandomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7)Immunotherapy20135101047105424088075
   PubMed Web of Science ®Google Scholar
• GuptaAAhmadFJAhmadFEfficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lungPLoS One201277e3921522844392
   PubMed Web of Science ®Google Scholar
• CardonaPJAmatIGordilloSImmunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosisVaccine200523111393139815661388
   PubMed Web of Science ®Google Scholar
• VilaplanaCGilOCaceresNPintoSDiazJCardonaPJProphylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosisPLoS One201165e2040421647222
   PubMed Web of Science ®Google Scholar
• VilaplanaCMontaneEPintoSDouble-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTIVaccine20102841106111619853680
   PubMed Web of Science ®Google Scholar
• NellASD’LomEBouicPSafety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infectionPLoS One201492e8961224586912
   PubMed Web of Science ®Google Scholar
• LowrieDBSilvaCLEnhancement of immunocompetence in tuberculosis by DNA vaccinationVaccine200018161712171610689154
   PubMed Web of Science ®Google Scholar
• OkadaMKitaYNakajimaTNovel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosisClin Dev Immunol2011201154928121437226
   PubMedGoogle Scholar
• TangheAD’SouzaSRosseelsVImproved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boostingInfect Immun20016953041304711292722
   PubMed Web of Science ®Google Scholar
• DerrickSCYangALMorrisSLA polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunityVaccine200423678078815542202
   PubMed Web of Science ®Google Scholar
• OkadaMKitaYNakajimaTNovel therapeutic vaccine: granulysin and new DNA vaccine against tuberculosisHum Vaccin20117Suppl606721546794
   PubMed Web of Science ®Google Scholar
• HerzogELChaiLKrauseDSPlasticity of marrow-derived stem cellsBlood2003102103483349312893756
   PubMed Web of Science ®Google Scholar
• SkrahinAAhmedRKFerraraGAutologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trialLancet Respir Med20142210812224503266
   PubMed Web of Science ®Google Scholar
• HoganBLYinglingJMEpithelial/mesenchymal interactions and branching morphogenesis of the lungCurr Opin Genet Dev1998844814869729726
   PubMed Web of Science ®Google Scholar
• SabatiniFPetecchiaLTavianMJodon de VillerocheVRossiGABrouty-BoyeDHuman bronchial fibroblasts exhibit a mesenchymal stem cell phenotype and multilineage differentiating potentialitiesLab Invest200585896297115924148
   PubMed Web of Science ®Google Scholar
• TropeaKALederEAslamMBronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasiaAm J Physiol Lung Cell Mol Physiol20123029L829L83722328358
   PubMed Web of Science ®Google Scholar
• SinclairKYerkovichSTChambersDCMesenchymal stem cells and the lungRespirology201318339741123316733
   PubMed Web of Science ®Google Scholar
• JoshiLChelluriLKGaddamSMesenchymal Stromal cell therapy in MDR/XDR tuberculosis: a concise reviewArch Immunol Ther Exp (Warsz)201563642743326100384
   PubMed Web of Science ®Google Scholar
• BatdelgerDDandiiDJirathitikalVBourinbaiarASOpen-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis CVaccine200826222733273718455842
   PubMed Web of Science ®Google Scholar
• ButovDAPashkovYNStepanenkoALPhase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TBJ Immune Based Ther Vaccines20119321244690
   PubMedGoogle Scholar
• ArjanovaOVPrihodaNDYurchenkoLVAdjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TBImmunotherapy20113218119121182457
   PubMed Web of Science ®Google Scholar
• ButovDAEfremenkoYVPrihodaNDAdjunct immune therapy of first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIVImmunotherapy20124768769522853755
   PubMed Web of Science ®Google Scholar
• JiaoXLo-ManRGuermonprezPDendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunityJ Immunol200216831294130111801668
   PubMed Web of Science ®Google Scholar
• FleschIKaufmannSHMycobacterial growth inhibition by interferon-gamma-activated bone marrow macrophages and differential susceptibility among strains of Mycobacterium tuberculosisJ Immunol198713812440844133108389
   PubMed Web of Science ®Google Scholar
• FengCGBeanAGHooiHBriscoeHBrittonWJIncrease in gamma interferon-secreting CD8(+), as well as CD4(+), T cells in lungs following aerosol infection with Mycobacterium tuberculosisInfect Immun19996773242324710377097
   PubMed Web of Science ®Google Scholar
• CondosRRomWNSchlugerNWTreatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosolLancet19973499064151315159167461
   PubMed Web of Science ®Google Scholar
• GiosueSCasariniMAmeglioFAerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosisEur Cytokine Netw20001119910410705306
   PubMed Web of Science ®Google Scholar
• KohWJKwonOJSuhGYSix-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosisJ Korean Med Sci200419216717115082886
   PubMed Web of Science ®Google Scholar
• BaluSReljicRLewisMJA novel human IgA monoclonal antibody protects against tuberculosisJ Immunol201118653113311921257971
   PubMed Web of Science ®Google Scholar
• JohnsonBJBekkerLGRickmanRrhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placeboTuber Lung Dis1997783–41952039713652
   PubMedGoogle Scholar
• JohnsonJLSsekasanvuEOkweraARandomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosisAm J Respir Crit Care Med2003168218519112702550
   PubMed Web of Science ®Google Scholar
• ShenHMinRTanQThe beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosisArch Med Sci201511358459026170852
   PubMed Web of Science ®Google Scholar
• ChenCYYaoSHuangDPhosphoantigen/IL2 expansion and differentiation of Vgamma2Vdelta2 T cells increase resistance to tuberculosis in nonhuman primatesPLoS Pathog201398e100350123966854
   PubMed Web of Science ®Google Scholar
• Fallahi-SichaniMFlynnJLLindermanJJKirschnerDEDifferential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeabilityJ Immunol201218873169317822379032
   PubMed Web of Science ®Google Scholar
• WallisRSKyambaddePJohnsonJLA study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosisAIDS200418225726415075543
   PubMed Web of Science ®Google Scholar
• Hernandez-PandoROrozco-EstevesHMaldonadoHAA combination of a transforming growth factor-beta antagonist and an inhibitor of cyclooxygenase is an effective treatment for murine pulmonary tuberculosisClin Exp Immunol2006144226427216634800
   PubMed Web of Science ®Google Scholar
• RoyEBrennanJJollesSLowrieDBBeneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infectionTuberculosis (Edinb)200888319720218096435
   PubMed Web of Science ®Google Scholar
• VordermeierHMVenkataprasadNHarrisDPIvanyiJIncrease of tuberculous infection in the organs of B cell-deficient miceClin Exp Immunol199610623123168918578
   PubMed Web of Science ®Google Scholar
• MaglionePJXuJChanJB cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosisJ Immunol2007178117222723417513771
   PubMed Web of Science ®Google Scholar
• LopezYYeroDFalero-DiazGInduction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16kDa protein in a model of progressive pulmonary infectionInt J Med Microbiol2009299644745219157977
   PubMed Web of Science ®Google Scholar
• RoyEStavropoulosEBrennanJTherapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in miceInfect Immun20057396101610916113331
   PubMed Web of Science ®Google Scholar
• HamasurBHaileMPawlowskiASchroderUKalleniusGSvensonSBA mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab’) fragment prolong survival of mice infected with Mycobacterium tuberculosisClin Exp Immunol20041381303815373902
   PubMed Web of Science ®Google Scholar
• de ValliereSAbateGBlazevicAHeuertzRMHoftDFEnhancement of innate and cell-mediated immunity by antimycobacterial antibodiesInfect Immun200573106711672016177348
   PubMed Web of Science ®Google Scholar
• Mayanja-KizzaHJones-LopezEOkweraAImmunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in UgandaJ Infect Dis2005191685686515717259
   PubMed Web of Science ®Google Scholar
• ChatterjeeSNutmanTBHelminth-induced immune regulation: implications for immune responses to tuberculosisPLoS Pathog2015111e100458225632943
   PubMed Web of Science ®Google Scholar
• AbateEBelaynehMIdhJAsymptomatic helminth infection in active tuberculosis is associated with increased regulatory and Th-2 responses and a lower sputum smear positivityPLoS Negl Trop Dis201598e000399426248316
   PubMed Web of Science ®Google Scholar
• SinghMMKumarPMalaviyaANKumarRLevamisole as an adjunct in the treatment of pulmonary tuberculosisAm Rev Respir Dis198112332772797013586
   PubMed Web of Science ®Google Scholar
• AbateEEliasDGetachewAEffects of albendazole on the clinical outcome and immunological responses in helminth co-infected tuberculosis patients: a double blind randomised clinical trialInt J Parasitol2015452–313314025486494
   PubMed Web of Science ®Google Scholar
• LiuPTStengerSLiHToll-like receptor triggering of a vitamin D-mediated human antimicrobial responseScience200631157681770177316497887
   PubMed Web of Science ®Google Scholar
• SelvarajPHarishankarMAfsalKVitamin D: Immuno-modulation and tuberculosis treatmentCan J Physiol Pharmacol201593537738425744368
   PubMed Web of Science ®Google Scholar
• BrunsHStegelmannFFabriMAbelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophagesJ Immunol201218984069407822988030
   PubMed Web of Science ®Google Scholar
• NapierRJRafiWCheruvuMImatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosisCell Host Microbe201110547548522100163
   PubMed Web of Science ®Google Scholar
• GoSILeeWSLeeGWNilotinib-induced interstitial lung diseaseInt J Hematol201398336136523877149
   PubMed Web of Science ®Google Scholar
• LeeNRJangJWKimHSYhimHYImatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infectionKorean J Intern Med201530455055326161025
   PubMed Web of Science ®Google Scholar
• SinghalAJieLKumarPMetformin as adjunct antituberculosis therapySci Transl Med20146263263ra159
   PubMed Web of Science ®Google Scholar
• PariharSPGulerRKhutlangRStatin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturationJ Infect Dis2014209575476324133190
   PubMed Web of Science ®Google Scholar
• StanleySABarczakAKSilvisMRIdentification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growthPLoS Pathog2014102e100394624586159
   PubMed Web of Science ®Google Scholar
• VilaplanaCMarzoETapiaGDiazJGarciaVCardonaPJIbuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosisJ Infect Dis2013208219920223564636
   PubMed Web of Science ®Google Scholar
• ByrneSTDenkinSMZhangYAspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosisJ Antimicrob Chemother200759231331617185297
   PubMed Web of Science ®Google Scholar
• Mayer-BarberKDAndradeBBOlandSDHost-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalkNature201451175079910324990750
   PubMed Web of Science ®Google Scholar
• MaigaMAmmermanNCMaigaMCAdjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatmentJ Infect Dis2013208351251923641020
   PubMed Web of Science ®Google Scholar
• SubbianSTsenovaLO’BrienPPhosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathologyAm J Pathol2011179128930121703411
   PubMed Web of Science ®Google Scholar
• ChenLWangJZganiaczAXingZSingle intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosisInfect Immun200472123824614688101
   PubMed Web of Science ®Google Scholar
• SantosuossoMZhangXMcCormickSWangJHittMXingZMechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumenJ Immunol2005174127986799415944305
   PubMed Web of Science ®Google Scholar
• SantosuossoMMcCormickSZhangXZganiaczAXingZIntranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosisInfect Immun20067484634464316861651
   PubMed Web of Science ®Google Scholar
• JeyanathanMHeriazonAXingZAirway luminal T cells: a newcomer on the stage of TB vaccination strategiesTrends Immunol201031724725220542470
   PubMed Web of Science ®Google Scholar